Geovax Labs Inc (GOVX) 0.1690 $GOVX GeoVax Provides

New Post Public Reply Private Reply Replies (0) Message Board

Apr 11, 2015 at 11:15 PM

Geovax Labs Inc (GOVX) 0.1690 $GOVX

GeoVax Provides Details of Presentation at World Vaccine Congress
Marketwired - Thu Apr 09, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today provided details of the talk presented by its Chief Scientific Officer, Harriet L. Robinson, Ph.D., at the World Vaccine Congress in Washington, D.C. The title of her talk was, "Phase 2 Development of a Prophylactic HIV Vaccine."

GeoVax Labs Issues Letter to Shareholders
Marketwired - Mon Apr 06, 9:30AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and Marburg viruses, and HIV using its novel platform technology, has provided shareholders with an annual update letter. The letter is distributed in GeoVax's 2014 Annual Report to Shareholders mailed on April 2, and can be read in full by visiting the following link: http://www.geovax.com/investors.html

GeoVax Provides Update on Its HIV Vaccine Program
Marketwired - Wed Apr 01, 9:30AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV, today announced that the HIV Vaccine Trials Network (HVTN) has assigned a trial number, HVTN 114, to the next clinical trial of its clade B preventive HIV vaccine candidate.

GeoVax's Chief Scientific Officer to Speak at World Vaccine Congress
Marketwired - Tue Mar 31, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today announced that Chief Scientific Officer Dr. Harriet L. Robinson, is invited to speak at the World Vaccine Congress to be held April 7-9, 2015 in Washington, DC. Dr. Robinson is scheduled to speak on April 8, 2015. The title of her talk is "Phase 2 Development of a Prophylactic HIV Vaccine."

GeoVax Appoints Industry Veteran to Its Board of Directors
Marketwired - Mon Mar 23, 8:01AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola and Marburg viruses, and HIV using its novel platform technology, today announced that it has appointed vaccine industry expert, Randal D. Chase, Ph.D. to its board of directors. This appointment brings the number of board members to six, four of whom are considered independent.
NVX: 14.52 (+0.08)

GeoVax Reports 2014 Year-End Financial Results
Marketwired - Fri Mar 20, 8:22AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2014, and provided the following corporate update.

GeoVax Provides Progress Report on Its Ebola Vaccine Program
Marketwired - Mon Jan 12, 8:01AM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its unique vaccine delivery platform, today provided an update on its Ebola virus vaccine development program.

GeoVax's Chief Scientific Officer Invited to Present at Dubai Scientific Conference
Marketwired - Wed Dec 10, 1:00PM CST
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D. will participate as an invited speaker at the 8th Dubai International Conference for Medical Sciences to be held on December 15-17, 2014 in Dubai, United Arab Emirates. Dr. Robinson will give two presentations entitled "Working towards an Ebola vaccine" and "Clade B VLP-expressing HIV vaccine."

SEC suspends trading in certain Ebola-related stocks
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 10:03AM CST

BCRX: 9.65 (+0.16), VSR: 3.13 (unch), TKMR: 18.19 (+0.59), NNVC: 2.08 (-0.03), INO: 9.78 (-0.18), CMRX: 37.54 (+0.36), APT: 2.23 (unch), HEB: 0.23 (+0.01), SRPT: 13.85 (-0.21), SMED: 6.63 (-0.02), PLX: 1.99 (-0.09), NLNK: 55.38 (-0.33), LAKE: 9.62 (-0.02), NSPH: 4.37 (-0.11)

Aethlon Medical up on successful Ebola treatment
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:06AM CST

BCRX: 9.65 (+0.16), VSR: 3.13 (unch), TKMR: 18.19 (+0.59), NNVC: 2.08 (-0.03), INO: 9.78 (-0.18), CMRX: 37.54 (+0.36), APT: 2.23 (unch), HEB: 0.23 (+0.01), SRPT: 13.85 (-0.21), SMED: 6.63 (-0.02), NLNK: 55.38 (-0.33), PLX: 1.99 (-0.09), LAKE: 9.62 (-0.02), NSPH: 4.37 (-0.11)

GeoVax reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 9:22AM CST

GeoVax Reports 2014 Third Quarter Financial Results
ACCESSWIRE - Tue Nov 11, 8:01AM CST
ATLANTA, GA / ACCESSWIRE / November 11, 2014 / GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, today announced financial results and recent developments for the three and nine months ended September 30, 2014.

GeoVax CEO Interviewed on the Fox Business Network
ACCESSWIRE - Thu Oct 30, 8:04AM CDT
Watch Robert McNally Discuss GeoVax's Ebola Vaccine Program

GeoVax Presents HIV Vaccine Clinical Trial Data
ACCESSWIRE - Wed Oct 29, 8:02AM CDT
Results of HIV Immunotherapy Vaccine Trial Presented at HIVR4P Conference

CDC issues new guidelines over Ebola
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:10AM CDT

BCRX: 9.65 (+0.16), VSR: 3.13 (unch), TKMR: 18.19 (+0.59), NNVC: 2.08 (-0.03), INO: 9.78 (-0.18), CMRX: 37.54 (+0.36), APT: 2.23 (unch), HEB: 0.23 (+0.01), SRPT: 13.85 (-0.21), SMED: 6.63 (-0.02), NLNK: 55.38 (-0.33), PLX: 1.99 (-0.09), LAKE: 9.62 (-0.02), NSPH: 4.37 (-0.11)

Mali confirms first Ebola case
Seeking Alpha - at Seeking Alpha - Fri Oct 24, 3:48AM CDT

BCRX: 9.65 (+0.16), GOLD: 71.19 (+1.43), AU: 10.24 (+0.72), VSR: 3.13 (unch), TKMR: 18.19 (+0.59), NNVC: 2.08 (-0.03), INO: 9.78 (-0.18), CMRX: 37.54 (+0.36), APT: 2.23 (unch), HEB: 0.23 (+0.01), SRPT: 13.85 (-0.21), SMED: 6.63 (-0.02), NLNK: 55.38 (-0.33), PLX: 1.99 (-0.09), LAKE: 9.62 (-0.02), NSPH: 4.37 (-0.11)

NYC doctor tests positive for Ebola; futures slip
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 8:57PM CDT

BCRX: 9.65 (+0.16), VSR: 3.13 (unch), TKMR: 18.19 (+0.59), NNVC: 2.08 (-0.03), INO: 9.78 (-0.18), SPY: 210.04 (+1.14), CMRX: 37.54 (+0.36), APT: 2.23 (unch), HEB: 0.23 (+0.01), SRPT: 13.85 (-0.21), SMED: 6.63 (-0.02), NLNK: 55.38 (-0.33), PLX: 1.99 (-0.09), LAKE: 9.62 (-0.02), NSPH: 4.37 (-0.11)

Ebola-stoked stocks rise
Seeking Alpha - at Seeking Alpha - Thu Oct 23, 2:49PM CDT

BCRX: 9.65 (+0.16), VSR: 3.13 (unch), TKMR: 18.19 (+0.59), NNVC: 2.08 (-0.03), INO: 9.78 (-0.18), CMRX: 37.54 (+0.36), APT: 2.23 (unch), HEB: 0.23 (+0.01), SRPT: 13.85 (-0.21), SMED: 6.63 (-0.02), NLNK: 55.38 (-0.33), PLX: 1.99 (-0.09), LAKE: 9.62 (-0.02), NSPH: 4.37 (-0.11)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...